More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...
Bacillus Calmette-Guérin (BCG) and Beyond: Is Systemic Immunotherapy for BCG-Naïve Non–Muscle-Invasive Bladder Cancer Progress or Overreach? The following represents disclosure information provided by ...
LAS VEGAS -- Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when patients received the PD-1 inhibitor sasanlimab in addition to bacillus ...
Adding immunotherapy to standard treatment for non-muscle invasive bladder cancer (NMIBC) achieved complete response (CR) in ...
Stocktwits on MSN
IBRX stock’s decline makes retail see ‘incredible’ buying opportunity after Anktiva + BCG therapy delivered favorable results
The data was presented at the 2026 American Urological Association Annual Meeting. ・Anktiva plus BCG showed a longer median duration of complete response of 22.1 months, compared with 9.7 months with ...
What Is BCG Treatment for Bladder Cancer? Bacillus Calmette-Guérin (BCG) is the main immunotherapy used to treat early-stage bladder cancer. Immunotherapy uses your immune system to fight cancer. BCG ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...
How can a tuberculosis vaccine also treat cancer—and potentially make other immunotherapies more effective? That’s the question researchers at Memorial Sloan Kettering Cancer Center (MSK) and Weill ...
Credit: Getty Images Investigators report encouraging findings from the phase 2 CORE-001 clinical trial. Treatment with cretostimogene plus pembrolizumab was associated with durable complete responses ...
Detalimogene voraplasmid achieved a 54.0% any-time CR in BCG-unresponsive NMIBC with CIS ± high-grade Ta/T1, with 91% of CRs ...
Stocktwits on MSN
IBRX stock rises overnight: Investors eye FDA workshop on Anktiva after exclusive Japan BCG deal
The FDA workshop will focus on whether CIS and papillary bladder cancer are biologically the same disease. ・ImmunityBio signed an exclusive agreement with a Japanese lab for the Tokyo-172 strain of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results